-DOCSTART- -X- O
Infectious -X- _ B-Patient
bronchitis -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
IBV -X- _ I-Patient
) -X- _ I-Patient
poses -X- _ O
a -X- _ O
severe -X- _ O
threat -X- _ O
to -X- _ O
the -X- _ O
poultry -X- _ O
industry -X- _ O
and -X- _ O
causes -X- _ O
heavy -X- _ O
economic -X- _ O
losses -X- _ O
worldwide. -X- _ O
Vaccination -X- _ O
is -X- _ O
the -X- _ O
most -X- _ O
effective -X- _ O
method -X- _ O
of -X- _ O
preventing -X- _ O
infection -X- _ O
and -X- _ O
controlling -X- _ O
the -X- _ O
spread -X- _ O
of -X- _ O
IBV -X- _ O
, -X- _ O
but -X- _ O
currently -X- _ O
available -X- _ O
inactivated -X- _ O
and -X- _ O
attenuated -X- _ O
virus -X- _ O
vaccines -X- _ O
have -X- _ O
some -X- _ O
disadvantages. -X- _ O
We -X- _ O
developed -X- _ O
a -X- _ O
chimeric -X- _ B-Intervention
virus-like -X- _ I-Intervention
particle -X- _ I-Intervention
( -X- _ I-Intervention
VLP -X- _ I-Intervention
) -X- _ I-Intervention
-based -X- _ I-Intervention
candidate -X- _ I-Intervention
vaccine -X- _ I-Intervention
for -X- _ O
IBV -X- _ O
protection. -X- _ O
The -X- _ O
chimeric -X- _ O
VLP -X- _ O
was -X- _ O
composed -X- _ O
of -X- _ O
matrix -X- _ O
1 -X- _ O
protein -X- _ O
from -X- _ O
avian -X- _ O
influenza -X- _ O
H5N1 -X- _ O
virus -X- _ O
and -X- _ O
a -X- _ O
fusion -X- _ O
protein -X- _ O
neuraminidase -X- _ O
( -X- _ O
NA -X- _ O
) -X- _ O
/ -X- _ O
spike -X- _ O
1 -X- _ O
( -X- _ O
S1 -X- _ O
) -X- _ O
that -X- _ O
was -X- _ O
generated -X- _ O
by -X- _ O
fusing -X- _ O
IBV -X- _ O
S1 -X- _ O
protein -X- _ O
to -X- _ O
the -X- _ O
cytoplasmic -X- _ O
and -X- _ O
transmembrane -X- _ O
domains -X- _ O
of -X- _ O
NA -X- _ O
protein -X- _ O
of -X- _ O
avian -X- _ O
influenza -X- _ O
H5N1 -X- _ O
virus. -X- _ O
The -X- _ O
chimeric -X- _ B-Outcome
VLPs -X- _ I-Outcome
elicited -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
S1-specific -X- _ I-Outcome
antibody -X- _ I-Outcome
responses -X- _ I-Outcome
in -X- _ I-Outcome
intramuscularly -X- _ I-Outcome
immunized -X- _ I-Outcome
mice -X- _ I-Outcome
and -X- _ I-Outcome
chickens -X- _ I-Outcome
than -X- _ I-Outcome
inactivated -X- _ I-Outcome
IBV -X- _ I-Outcome
viruses. -X- _ I-Outcome
Furthermore -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
chimeric -X- _ I-Outcome
VLPs -X- _ I-Outcome
induced -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
neutralization -X- _ I-Outcome
antibody -X- _ I-Outcome
levels -X- _ I-Outcome
than -X- _ I-Outcome
inactivated -X- _ I-Outcome
H120 -X- _ I-Outcome
virus -X- _ I-Outcome
in -X- _ I-Outcome
SPF -X- _ I-Outcome
chickens. -X- _ I-Outcome
Finally -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
chimeric -X- _ I-Outcome
VLPs -X- _ I-Outcome
induced -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
IL-4 -X- _ I-Outcome
production -X- _ I-Outcome
in -X- _ I-Outcome
mice. -X- _ I-Outcome
These -X- _ O
results -X- _ O
demonstrate -X- _ O
that -X- _ O
chimeric -X- _ O
VLPs -X- _ O
have -X- _ O
the -X- _ O
potential -X- _ O
for -X- _ O
use -X- _ O
in -X- _ O
vaccines -X- _ O
against -X- _ O
IBV -X- _ O
infection -X- _ O
. -X- _ O

